MedTrace Logo

Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.

NCT04500860 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-08-15

No results posted yet for this study

Summary

Evaluation of use of low dose tadalafil 5 mg daily for treatment of female OAB syndrome

Conditions

  • Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence

Interventions

DRUG

Low dose tadalafil 5 mg

Efficacy of daily low dose tadalafil 5mg for treatment of female overactive bladder syndrome or urgency with or without urgency urinary incontinence

DRUG

Tolterodine 4 Mg Oral Capsule, Extended Release

To compare efficacy of low dose tadalafil 5 mg to tolterodine 4 mg extended release in treatment of female overactive bladder

DRUG

Placebo

Placebo drugs

Sponsors & Collaborators

  • Kasr El Aini Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2022-07-01
Completion
2022-07-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04500860 on ClinicalTrials.gov